Matching trials
1,853 results
- NOHARMIndependent statistical analysis of Novel Use Of Hydroxyurea in an African Region With Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01976416).
- NOR-TESTIndependent statistical analysis of the NOR-TEST phase 3 trial comparing tenecteplase versus alteplase for thrombolysis in acute ischemic stroke, including trial design, endpoints, methodology, and statistical interpretation.
- NOR-TEST 2An educational statistical analysis of NOR-TEST 2, a randomized phase 3 trial comparing tenecteplase with alteplase in acute ischemic stroke, focusing on its 90-day favorable functional outcome endpoint and statistical design.
- NOSE-400Independent statistical analysis of A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NOTUSIndependent statistical analysis of the phase 3 NOTUS trial of dupilumab versus placebo in moderate to severe COPD with type 2 inflammation: negative binomial exacerbation-rate analysis, MMRM lung-function and SGRQ results, hierarchical…
- NOVA2Independent statistical analysis of Inhaled Nitric Oxide and Neuroprotection in Premature Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515281).
- NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies: Complete Statistical AnalysisIndependent statistical analysis of NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NSABP B-27Independent statistical analysis of NSABP B-27, a randomized phase 3 trial evaluating preoperative or postoperative Taxotere after preoperative AC in women with surgically removable breast cancer.
- NSABP B-31An independent statistical analysis of NSABP B-31, the randomized phase 3 trial of doxorubicin and cyclophosphamide plus paclitaxel with or without trastuzumab in women with node-positive HER2-overexpressing breast cancer.
- NSABP B-38Independent statistical analysis of NSABP B-38, a randomized phase 3 trial of combination chemotherapy in women who underwent surgery for node-positive breast cancer, including its design, disease-free survival endpoint, statistical methodology, safety…
- NSABP B-41An independent statistical analysis of NSABP B-41, a randomized phase 3 study of AC followed by paclitaxel plus trastuzumab, lapatinib, or both before surgery in patients with operable HER2-positive invasive breast cancer.
- NSABP R-04Independent statistical analysis of NSABP R-04, a randomized phase 3 trial evaluating radiation therapy with capecitabine or fluorouracil, with or without oxaliplatin, before surgery in patients with resectable rectal cancer.
- Nutraceutical Efficacy for rUTI: Complete Statistical AnalysisIndependent statistical analysis of Nutraceutical Efficacy for rUTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395288).
- OAKTREEComplete statistical analysis of the randomized phase 3 OAKTREE trial of obeldesivir in nonhospitalized participants with COVID-19, including trial design, endpoints, survival analysis, viral-load analysis, safety, statistical methodology, results, and interpretation.
- OARS-PilotIndependent statistical analysis of Opioid Analgesic Reduction Study (OARS) - Pilot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05283499).
- OASIS-1Independent statistical analysis of A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal…
- OASIS-4Independent statistical analysis of A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy…
- OASIS-5Independent statistical analysis of OASIS-5, a randomized phase 3 trial comparing fondaparinux with enoxaparin in thromboembolism, including its design, primary endpoints, planned statistical analysis, and interpretation.
- OASIS-6An independent statistical analysis of OASIS-6, a randomized phase 3 trial evaluating fondaparinux versus control therapy in patients with ST-segment elevation acute myocardial infarction.
- OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE): Complete Statistical AnalysisIndependent statistical analysis of OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE): primary endpoint results, effect estimate with confidence…
- OASIS(CM)Independent statistical analysis of Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- OE05Independent statistical analysis of the OE05 phase 3 randomized trial of combination chemotherapy in patients with esophageal cancer, including its design, survival endpoint, planned statistical analysis, and interpretation.
- OHTSIndependent statistical analysis of Ocular Hypertension Treatment Study (OHTS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00000125).
- OIIndependent statistical analysis of Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLE-IEDATIndependent statistical analysis of Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Omarigliptin (MK-3102) Clinical Trial – Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): Complete Statistical AnalysisIndependent statistical analysis of Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): primary endpoint results, effect estimate with confidence interval,…
- Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00511810).
- onceMRKIndependent statistical analysis of Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292): primary…
- One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age: Complete Statistical AnalysisIndependent statistical analysis of One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response…
- One Year Study of Rifaximin Delayed Release (DR) in Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online Caregiver Psychoeducation and Support for Alzheimer’s: Complete Statistical AnalysisIndependent statistical analysis of Online Caregiver Psychoeducation and Support for Alzheimer's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00416078).
- ONPEDIndependent statistical analysis of Oral Naltrexone In Pediatric Eating Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073679).
- onset 9Independent statistical analysis of onset 9, a randomized phase 3 trial comparing faster-acting insulin aspart with NovoRapid in people with type 2 diabetes, including its non-inferiority analysis of HbA1c change.
- onset® 1Complete statistical analysis of the onset® 1 phase 3 trial of faster-acting insulin aspart compared with insulin aspart in adults with type 1 diabetes, including the randomized design, HbA1c endpoint, MMRM methodology,…
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): primary endpoint results, effect estimate with confidence…
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults: Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults: primary endpoint results, effect estimate with…
- Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02904902).